MRIA9

Item no.	HY-139253-50mg
Manufacturer	MedChem Express
CASRN	2750707-05-0
Amount	50 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	98.34
Formula	C24H22ClFN6O3
Citations	[1]Roberta Tesch, et al. Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors. J Med Chem. 2021 Jun 24;64(12):8142-8160.<br>[2]Monika Raab, et al. The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells. Cancers 2021, 13(15), 3658.
Smiles	N[C@@H](CO1)CO[C@H]1CN(C2=O)C3=NC(NC)=NC=C3C=C2C4=CC=C(C=C4Cl)C5=NC=CC=C5F
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Available
Product Description	MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC50 values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	496.92
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 66.67 mg/mL (ultrasonic)
Manufacturers Target	Apoptosis; PAK; Salt-inducible Kinase (SIK)
Isoform	SIK1; SIK2; SIK3
Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 50 mg

available

Request delivery time